Clinical Trials Logo

Breast Neoplasms clinical trials

View clinical trials related to Breast Neoplasms.

Filter by:

NCT ID: NCT02642094 Terminated - Cancer of Breast Clinical Trials

Aging Mammary Stem Cells and Breast Cancer Prevention

Start date: July 2016
Phase: Phase 2
Study type: Interventional

To examine whether rapamycin can reduce malignant markers and aberrant mammary stem/progenitor cells (MaSCs) number in surgical specimens

NCT ID: NCT02624700 Terminated - Breast Cancer Clinical Trials

2nd Line Treatment With Pemetrexed and Sorafenib for Recurrent or Metastatic Triple Negative Breast Cancer

Start date: January 28, 2016
Phase: Phase 2
Study type: Interventional

This phase 2 clinical trial will evaluate the efficacy of the combination of pemetrexed and sorafenib in patients with recurrent or metastatic Triple Negative Breast Cancer (TNBC). Candidate pharmacodynamic and predictive biomarkers will also be evaluated.

NCT ID: NCT02611310 Terminated - Clinical trials for Metastatic Breast Cancer

A Study to Observe Treatment Patterns and Outcomes in Participants in Saudi Arabia With Human Epidermal Growth Factor Receptor 2 (HER2-Positive) Unresectable Locally Advanced or Metastatic Breast Cancer (LA/mBC)

Start date: January 19, 2017
Phase:
Study type: Observational

This is a prospective, national, multicenter, non-interventional study designed to enroll participants who have an initial diagnosis of unresectable LA/mBC made up to 6 months prior to registry enrollment. These participants will be prospectively followed for at least 5 years after study enrollment to evaluate their anti-cancer treatments. Data on participants' previous anti-cancer treatments for breast cancer will be collected retrospectively at study entry.

NCT ID: NCT02602067 Terminated - Clinical trials for Lymphoma, Non-Hodgkin

131Iodine-Tenatumomab Treatment in Tenascin-C Positive Cancer Patients

Tenatumomab
Start date: November 2015
Phase: Phase 1
Study type: Interventional

Tenatumomab is a Sigma-Tau developed new anti-Tenascin antibody. It is a murine monoclonal antibody directed towards Tenascin-C. By means of this antibody, Tenascin-C expression was studied on a commercial tissue array slides each carrying malignant breast, colorectal, lung, ovarian or B and T cell Non-Hodgkin Limphoma tissue sections. All these cancers type showed positivity to Tenascin-C between the 64% and 13.3%. Consequently, Sigma-tau is exploring the use of the 131I-labeled Tenatumomab for anti-cancer radioimmunotherapy.

NCT ID: NCT02598427 Terminated - Clinical trials for HER2 Positive Untreated Metastatic Breast Cancer

Intrathecal Pertuzumab and Trastuzumab in Patients With New Untreated Asymptomatic or Low Symptomatic Brain Metastasis in HER2 Positive Breast Cancer

Start date: May 1, 2017
Phase: Phase 1
Study type: Interventional

The purpose of this research study is to determine how well pertuzumab and trastuzumab works in treating breast cancer that has spread to the brain. Pertuzumab and trastuzumab are treatments that stop breast cancer cells from growing abnormally by inhibiting (or blocking) members of a family of proteins that include Human Epidermal Growth Factor Receptor 2 (HER2). Pertuzumab and trastuzumab have been found to be very effective for HER2-positive breast cancer and are FDA approved for treatment of metastatic breast cancer outside of the brain when given through the vein. This suggests that pertuzumab and trastuzumab may help shrink or stabilize HER2-positive breast cancer that has spread to the brain in this research study. In this research study, the investigators are looking to see whether pertuzumab and trastuzumab will work to decrease the size of or stabilize breast cancer that has spread to the brain.

NCT ID: NCT02598310 Terminated - Breast Cancer Clinical Trials

Neoadjuvant Nab-PTX and Trastuzumab for ER Negative and HER2 Positive Breast Cancer

Start date: November 2015
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of nab-PTX and trastuzumab for ER negative and HER2 positive operable (tumor size of 3cm or less and N0) breast cancer.

NCT ID: NCT02596867 Terminated - Breast Cancer Clinical Trials

Neoadjuvant Propanolol in Breast Cancer

NPBC
Start date: September 1, 2015
Phase: Phase 2
Study type: Interventional

This trial is a Phase II study using the "window-of-opportunity" design in which the treatment-free window between breast cancer diagnosis and surgical tumor resection is used to study the biological effects of the beta blocker propranolol .

NCT ID: NCT02585388 Terminated - Breast Cancer Clinical Trials

Addition of Aromatase at the Navelbine in Pretreated Metastatic Breast Cancer.

CHEOPS
Start date: October 23, 2015
Phase: Phase 2
Study type: Interventional

The CHEOPS study aims to confirm the clinical benefit of a combination of an anti-aromatase and metronomic chemotherapy treatment

NCT ID: NCT02582801 Terminated - Breast Cancer Clinical Trials

Clinical Research of 18F-Alfatide Ⅱ PET/CT in Breast Cancer

Start date: October 2015
Phase: Phase 1
Study type: Interventional

18F-Alfatide Ⅱ PET/CT in breast cancer patients

NCT ID: NCT02581709 Terminated - Breast Neoplasms Clinical Trials

An Intervention Programme to Reduce Cognitive Impairment Due to Cancer

Start date: May 2016
Phase: N/A
Study type: Interventional

The goal of this research study is to test the feasibility of an intervention programme to reduce cognitive impairment due to cancer treatment. The investigators want to find out how acceptable the intervention and procedures are for cancer patients.